Jianhong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianhong Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Ding Ding
Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Center for Neurological Disorders, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China
4 shared publicationsHonglu Ping
Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Center for Neurological Disorders, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China
4 shared publications- Jun Zhang
Department of Radiology, Huashan hospital, Fudan University, Shanghai, China
3 shared publications Xiaowen Zhou
Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Center for Neurological Disorders, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China
3 shared publicationsYiling Chen
Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Center for Neurological Disorders, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China
3 shared publicationsGuoxing Zhu
Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China; National Center for Neurological Disorders, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China
2 shared publications
Latest Publications
- 17 June 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111166
Sex difference in the association of antiseizure medication load with cognitive decline in older people with epilepsy: A prospective study
- 17 June 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111166
Sex difference in the association of antiseizure medication load with cognitive decline in older people with epilepsy: A prospective study
- 18 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110889
Sleep quality and impact factors in older adults with epilepsy
- 18 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110889
Sleep quality and impact factors in older adults with epilepsy
- Open Access
- 7 September 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102297
Epileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication
- 7 September 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102297
Open AccessEpileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication
- Open Access
- 23 May 2025
- Published by Springer Nature in Acta Epileptologica
- Vol. 7 (1) , 1-8
Seizure frequency, APOE ε4, and cognitive function in older people with epilepsy
Background: Cognitive impairment represents a major comorbidity among older adults with epilepsy. This study aimed to explore the association between the apolipoprotein E (APOE) ε4 allele and cognitive function in older people with epilepsy. Methods: People with epilepsy aged ≥ 50 years were enrolled at an outpatient clinic of epilepsy from November 2019 to July 2024. Blood samples were collected for APOE genotyping. Participants were categorized into two groups based on the presence of the APOE ε4 allele: APOE ε4 (+/-). Cognitive function was assessed using a battery with neuropsychological tests. Based on Mini-Mental State Examination (MMSE) scores, participants were defined as unimpaired cognition (UC) (MMSE ≥ 27) and cognitive impairment (CI) (MMSE < 27). Seizure frequency was categorized into low (≤ 3/year) and high (> 3/year) groups. Multivariate logistic regression analysis and general linear models were employed to identify factors associated with cognitive function. Results: Among 110 participants, 51 (46.4%) were defined as CI. Compared with UC group, the CI group was older (65.1 ± 7.6 vs 60.8 ± 6.8 years, P = 0.002), with lower educational level (9.0 [7.0, 11.0] vs 12.0 [9.0, 13.0] years, P < 0.001), and higher seizure frequency (12.0 [1.0, 24.0] vs 1.0 [0.0, 12.0] times/year, P = 0.005). High seizure frequency (OR = 3.94, 95% CI [1.34, 11.61], P = 0.013) and more APOE ε4 alleles (OR = 3.28, 95% CI [1.09, 9.83], P = 0.034) were risk factors for CI. An interactive effect between the number of APOE ε4 alleles and seizure frequency was observed (P = 0.002). Compared to participants with APOE ε4 (-) and low seizure frequency, those with APOE ε4 (-) and high seizure frequency showed a threefold risk of CI (OR = 3.34, 95% CI [0.99, 11.25], P = 0.051), while those with APOE ε4 (+) and high frequency demonstrated the highest risk of CI (OR = 10.53, 95% CI [1.75, 63.47], P = 0.010). Conclusions: The synergistic effect of APOE ε4 allele and seizure frequency on cognitive function suggested their importance in clinical assessments and therapeutic approaches in managing older people with epilepsy.
- 23 May 2025
- Published by Springer Nature in Acta Epileptologica
- Vol. 7 (1) , 1-8
Open AccessSeizure frequency, APOE ε4, and cognitive function in older people with epilepsy
Background: Cognitive impairment represents a major comorbidity among older adults with epilepsy. This study aimed to explore the association between the apolipoprotein E (APOE) ε4 allele and cognitive function in older people with epilepsy. Methods: People with epilepsy aged ≥ 50 years were enrolled at an outpatient clinic of epilepsy from November 2019 to July 2024. Blood samples were collected for APOE genotyping. Participants were categorized into two groups based on the presence of the APOE ε4 allele: APOE ε4 (+/-). Cognitive function was assessed using a battery with neuropsychological tests. Based on Mini-Mental State Examination (MMSE) scores, participants were defined as unimpaired cognition (UC) (MMSE ≥ 27) and cognitive impairment (CI) (MMSE < 27). Seizure frequency was categorized into low (≤ 3/year) and high (> 3/year) groups. Multivariate logistic regression analysis and general linear models were employed to identify factors associated with cognitive function. Results: Among 110 participants, 51 (46.4%) were defined as CI. Compared with UC group, the CI group was older (65.1 ± 7.6 vs 60.8 ± 6.8 years, P = 0.002), with lower educational level (9.0 [7.0, 11.0] vs 12.0 [9.0, 13.0] years, P < 0.001), and higher seizure frequency (12.0 [1.0, 24.0] vs 1.0 [0.0, 12.0] times/year, P = 0.005). High seizure frequency (OR = 3.94, 95% CI [1.34, 11.61], P = 0.013) and more APOE ε4 alleles (OR = 3.28, 95% CI [1.09, 9.83], P = 0.034) were risk factors for CI. An interactive effect between the number of APOE ε4 alleles and seizure frequency was observed (P = 0.002). Compared to participants with APOE ε4 (-) and low seizure frequency, those with APOE ε4 (-) and high seizure frequency showed a threefold risk of CI (OR = 3.34, 95% CI [0.99, 11.25], P = 0.051), while those with APOE ε4 (+) and high frequency demonstrated the highest risk of CI (OR = 10.53, 95% CI [1.75, 63.47], P = 0.010). Conclusions: The synergistic effect of APOE ε4 allele and seizure frequency on cognitive function suggested their importance in clinical assessments and therapeutic approaches in managing older people with epilepsy.
- Open Access
- 23 July 2024
- Published by Springer Nature in Acta Epileptologica
- Vol. 6 (1) , 1-10
Advancements in the application of nanotechnology for the management of epileptic seizures
Epilepsy is a common yet complex neurological disorder. Historically, antiseizure medications (ASMs) have faced challenges in crossing the blood-brain barrier (BBB) and targeting the epileptogenic zone, creating a bottleneck in seizure management. Certain nanomaterials can facilitate drug penetration through the BBB and enable stimulus-responsive drug release, thereby enhancing targeted and efficient drug utilization while reducing adverse reactions in other brain tissues and peripherally. This article reviews the current researches on stimulus-responsive nanosystems applicable in antiepileptic therapy, as well as nanotechnology applications that improve the brain delivery of ASMs.
- 23 July 2024
- Published by Springer Nature in Acta Epileptologica
- Vol. 6 (1) , 1-10
Open AccessAdvancements in the application of nanotechnology for the management of epileptic seizures
Epilepsy is a common yet complex neurological disorder. Historically, antiseizure medications (ASMs) have faced challenges in crossing the blood-brain barrier (BBB) and targeting the epileptogenic zone, creating a bottleneck in seizure management. Certain nanomaterials can facilitate drug penetration through the BBB and enable stimulus-responsive drug release, thereby enhancing targeted and efficient drug utilization while reducing adverse reactions in other brain tissues and peripherally. This article reviews the current researches on stimulus-responsive nanosystems applicable in antiepileptic therapy, as well as nanotechnology applications that improve the brain delivery of ASMs.